239 related articles for article (PubMed ID: 33634878)
1. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
Beltjens F; Molly D; Bertaut A; Richard C; Desmoulins I; Loustalot C; Charon-Barra C; Courcet E; Bergeron A; Ladoire S; Jankowski C; Boidot R; Arnould L
Int J Cancer; 2021 Jul; 149(1):200-213. PubMed ID: 33634878
[TBL] [Abstract][Full Text] [Related]
2. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
3. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
4. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
5. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
8. IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.
Christgen M; Geffers R; Kreipe H; Lehmann U
Cancer Sci; 2013 Dec; 104(12):1726-30. PubMed ID: 24344720
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
12. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
15. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
16. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
[TBL] [Abstract][Full Text] [Related]
17. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
18. Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance?
Killelea BK; Chagpar AB; Bishop J; Horowitz NR; Christy C; Tsangaris T; Raghu M; Lannin DR
Ann Surg Oncol; 2013 Oct; 20(10):3247-53. PubMed ID: 23975299
[TBL] [Abstract][Full Text] [Related]
19. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
20. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]